Novelix Pharmaceuticals Ltd.
Fundamentals
- Market cap
- ₹191 cr
- P/E
- 74.76×
- ROE
- 0.48%
- Debt / equity
- 0.00
- 52-week range
- 32.32 — 92.00
Company snapshot
Novelix Pharmaceuticals Ltd.
Miscellaneous
₹186 cr
P/E 72.76×
Latest quarter · Dec 2022
Sales−₹2 cr
Net profit₹0 cr
Op. margin−0.3%
EPS₹0.22
Strength & growth
Debt / equity0.02×
Current ratio6.38×
Sales CAGR+36.9%
EPS CAGR+43.1%
The timeline — 4 notes on Novelix Pharmaceuticals Ltd.
June 2026
- 04 Jun 26 · 10:49 PM IST Lead Lead · Micro cap
Novelix is selling 5% of itself to 18 investors for ₹6.84 cr.
The board approved a preferential issue at ₹57 a share, a ₹47 premium to face value. Shareholder approval is needed by July 2026.
- 03 Jun 26 · 3:47 PM IST Brief Brief · Micro cap
Novelix signs German deal to commercialize Astaxanthin production
The nano-cap pharmaceutical firm has locked in a partner to scale its antioxidant from pilot to commercial output, but no financial terms are disclosed.
- 01 Jun 26 · 8:42 PM IST Brief Brief · Micro cap
Novelix Pharmaceuticals preps another equity raise
The board will meet to approve a preferential issue. It's the latest capital call from a nano-cap with a market cap of ₹131 cr and a history of frequent dilutive raises.